Axonis Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 Kneeland St Fl 14, Boston, Massachuse...Website
www.axonis.usRevenue
<$5 MillionIndustry
About Axonis Therapeutics
Founded in 2019, based out of Cambridge, MA, AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders. AXONIS is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and PTEN inhibition to regenerate injured nerve connections, to make a real difference for patients, their families, and the global healthcare system.Explore more
Axonis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Axonis Therapeutics
Compare insights from companies similar to Axonis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Axonis Therapeutics Tech Stack
A closer look at the technologies used by Axonis Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Axonis Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2019, based out of Cambridge, MA, AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders. AXONIS is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and P... Read More
